Letter: Medical imports placed at risk by likely exit path
In response to Jonathan Ford's article yesterday, Regulation risk to medicines overplayed, Martin Sawer, Executive Director of HDA UK, wrote a letter to the Financial Times. His letter re-evaluates the impact of Brexit on the UK pharmaceutical industry. Printed in the Financial Times, the letter critiques Jonathan Ford's underestimation of the potential negative impact on the medicines supply chain in the UK after leaving the European Union. As the Association that represents companies responsible for distributing 92% of NHS medicines, the HDA looks forward to working with the Government, regulators and supply chain partners to ensure that UK patients are not negatively affected by the vote to leave the European Union.